AZN +1.5% on phase-3 Lynparza data in BRCA+ breast cancer: http://finance.yahoo.com/news/lynparza-olaparib-meets-primary-endpoint-120000191.html AstraZeneca today announced positive results from its Phase III OlympiAD trial comparing LYNPARZA (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA1 or BRCA2 mutations. Patients treated with LYNPARZA showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared with those who received chemotherapy (capecitabine, vinorelbine or eribulin). AstraZeneca will be working with regulatory authorities to make LYNPARZA available to patients with this type of breast cancer.